相关实验视频
Updated: Jun 13, 2025
08:50
Predictive Immune Modeling of Solid Tumors
Published on: February 25, 2020
6.9K
检查点抑制剂在恶性固体瘤中的预测生物标志物和抵抗机制
Luciana Alexandra Pavelescu1, Robert Mihai Enache2, Oana Alexandra Roşu1,3
1Department of Morphological Sciences, Cell and Molecular Biology and Histology, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania.
International journal of molecular sciences
|September 14, 2024
概括
肠道微生物组显著影响免疫检查点抑制剂 (ICI) 在固体瘤中的有效性. 了解微生物群与免疫疗法的相互作用是改善治疗结果和开发组合策略的关键.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 微生物学 微生物学
背景情况:
- 固体瘤中免疫检查点抑制剂 (ICI) 的预测生物标志物包括PD-L1表达,TMB,dMMR,MSI和TME.
- 针对CTLA-4,PD-1,PD-L1和LAG-3的各种ICI已经获得批准,其他ICI的研究正在进行中.
- 新出现的证据强调了肠道微生物组在调节ICI治疗反应中的关键作用.
研究的目的:
- 综合有关肠道微生物群与癌症免疫治疗 (IT) 之间的复杂相互作用的当前数据.
- 突出影响健康微生物群的因素对于优化ICI治疗的重要性.
- 探索抵抗机制及其与瘤微环境及其与替代免疫检查点的关系.
主要方法:
- 文献审查和数据综合.
- 对ICI预测生物标志物的现有研究进行分析.
- 检查对肠道微生物群对免疫疗法反应和耐药性的影响的研究.
主要成果:
- 肠道微生物组在确定患者对各种固体瘤的ICI反应方面发挥着至关重要的作用.
- 对ICI的耐药性可能来自替代免疫检查点 (TIM-3,LAG-3),抗原呈现受损和TME变化.
- 保持健康的肠道微生物组对于最大限度地提高免疫疗法的疗效至关重要.
结论:
- 了解微生物群和免疫治疗之间的相互作用对于提高ICI疗效至关重要.
- 对微生物组调节策略的进一步研究可能会导致改善固体瘤的组合疗法.
- 准肠道微生物组是克服抗癌免疫疗法的有希望的途径.
相关概念视频
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
01:27Tumor Immunotherapy
491
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
491
02:34Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K